Journal
LEUKEMIA RESEARCH
Volume 39, Issue 2, Pages 248-256Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2014.11.023
Keywords
Burkitt lymphoma; CDKN2A; Methylation; p16(INK4a); Pyrosequencing; Survival
Categories
Funding
- INCT para Controle do Cancer [CNPq 573806/2008-0, FAPERJ E26/170.026/2008]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Ministerio da Saude/INCA
Ask authors/readers for more resources
CDKN2A is a tumor suppressor gene critical in the cell cycle regulation. Little is known regarding the role of CDKN2A methylation in the pathogenesis of Burkitt lymphoma (BL). CDKN2A methylation was investigated using pyrosequencing in 51 tumor samples. p16(INK4a) mRNA and protein levels were measured using real-time PCR and immunohistochemistry, respectively. CDKN2A methylation was detectable in 72% cases. Nuclear expression of p16(INK4a) was not detected in 41% cases. There was an association between methylation and absence of CDKN2A mRNA (P=0.003). In conclusion, CDKN2A methylation occurs at a high frequency suggesting a role in BL pathogenesis and potential therapeutic implications. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available